tbuckley/cabot-search huggingface dataset:
Radiosensitization of HER2-positive breast cancer cell lines with trastuzumab.
Authors: Senem Demirci Alanyali, Emir Bozkurt, Hilmi Alanyali, Burcak Karaca, Ruchan Uslu
Journal: Journal of Clinical Oncology (2013)

e11501 Background: HER2 is a member of the human epidermal growth factor (EGF) receptor family that is blocked by a monoclonal antibody, Trastuzumab (Herceptin). In daily clinical practice, Trastuzumab is being used concurrently with radiotherapy (RT) in breast cancer patients. Administration of Trastuzumab with RT appear to be safe in regard to cardiac morbidity and mortality in patients with relatively modest follow-up duration (less than 5 years). In this study we aimed to determine the possible interactions between RT and Trastuzumab in HER2 positive breast cancer cell line MDA-MB-453. Methods: MDA-MB-453 cells were treated with increased dose of Trastuzumab (10 – 200 µg/mL, 72 hours) and irradiation (0-8 Gy, 4 Gy/min, 48 hours). XTT (Roche) viability assay was used to measure the cytotoxicity of Trastuzumab, and trypan blue method was used to measure the cytotoxicity of irradiation. The sensitization of MDA-MB-453 cell lines was done by IC50 of Trastuzumab with 24 hours treatment followed by 6 and 8 Gy irradiation. Results: Cytotoxicity was increased in a dose and time dependent manner by Trastuzumab and irradiation treatment in MDA-MB-453 cell lines. IC50 values of Trastuzumab and irradiation were found to be 167 µg/mL and 8 Gy, at 48 hours, respectively.Cells were pretreated with IC25 and IC50 doses of Trastuzumab for 24 hours and then irradiated with 6 and 8 Gy doses. The cell viability at 24 and 48 hours were significantly decreased (p=0.0012) compared to single exposures (Trastuzumab or irradiation), indicating that Trastuzumab sensitizes HER2 positive breast cancer cells to irradiation. Conclusions: This preliminary study showed the sensitization effect of Trastuzumab to irradiation in HER2 positive breast cancer cells. Further studies are warranted for the optimal dosing and normal tissue toxicity of this combination.
Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial
Authors: Marc Bourlière, Pascaline Rabiega, Nathalie Ganne-Carrie, Lawrence Serfaty, Patrick Marcellin, Yoann Barthe, Dominique Thabut, Dominique Guyader, Christophe Hezode, Magali Picon, Xavier Causse, Vincent Leroy, Jean Pierre Bronowicki, Patrizia Carrieri, Ghassan Riachi, Isabelle Rosa, Pierre Attali, Jean Michel Molina, Yannick Bacq, Albert Tran, Jean Didier Grangé, Fabien Zoulim, Hélène Fontaine, Laurent Alric, Inga Bertucci, Magali Bouvier-Alias, Fabrice Carrat
Journal: The Lancet. Gastroenterology & hepatology (2017)
VE-BASKET, a first-in-kind, phase II, histology-independent “basket” study of vemurafenib (VEM) in nonmelanoma solid tumors harboring BRAF V600 mutations (V600m).
Authors: David Michael Hyman, Jean-Yves Blay, Ian Chau, Noopur S. Raje, Maria Elena Elez Fernandez, Juergen Wolf, Florin Sirzen, Maria Luisa Veronese, Lada Mitchell, Igor Puzanov, Jose Baselga
Journal: Journal of Clinical Oncology (2014)

2533^ Background: Low prevalence of V600m in non-melanoma cancers requires a novel trial design to assess the activity of BRAF inhibitors. We undertook a histology-independent, "basket" study of VEM in BRAFV600m-positive cancers (NCT01524978). Six disease cohorts were prespecified, remaining tumors were enrolled to a 7th "all-comers" cohort. Here we present preliminary efficacy and safety data for the non-small cell lung cancer (NSCLC), cholangiocarcinoma (CLC), and Erdheim-Chester disease (ECD)/Langerhans cell histiocytosis (LCH) cohorts. Methods: Multicenter Simon 2-stage adaptive design in adult patients (pts; majority pretreated) with metastatic V600m-positive cancers receiving VEM (960 mg bid) until investigator (INV)-assessed disease progression (PD) or unacceptable toxicity. Primary endpoint is INV-assessed response rate (RR) at week 8 (RECIST v1.1). Secondary objectives include overall RR, clinical benefit rate, duration of response, progression-free survival, overall survival, and safety. Results: 95 pts have been enrolled (04/2012-12/2013). Median treatment duration (days, range) was 121 (32-449) in NSCLC, 61 (29-451) in CLC, 168 (39-435) in ECD/LCH. In NSCLC, 8/19 pts had unconfirmed partial responses (uPRs) (wk 8, stage II) and 8/19 pts stable disease (SD). 6 uPRs were subsequently confirmed. At stage I CLC analysis, 4/7 pts had SD, 3/7 pts had PD (wk 8). By wk 24, 2 pts converted to PR. At stage I ECD/LCH analysis, 7 pts were enrolled (1 pt not evaluable for response). A confirmed CR was observed in 1/6 pts and SD in 5/6 pts. By wk 16, 2 pts converted to PR. Moving to stage II, 3 further pts have been enrolled, showing 1 SD and 2 PR at wk 8. All 9 evaluable ECD/LCH pts had shrinkage of target lesions, median change (%, range) from baseline was -18% (5-100) at wk 8 and -30% (7-100) at wk 16. Safety data were consistent with prior pivotal VEM studies. Conclusions: Histology-independent trials of rare molecularly defined populations are feasible and yield important signals of activity. VEM has promising activity in pts with V600m-positive NSCLC, CLC, and ECD/LCH. Updated efficacy results from all patients will be provided at the time of ASCO. Clinical trial information: NCT01524978.
Dysregulation of hedgehog pathway signaling in hepatocellular carcinoma
Authors: Eric R. Lemmer, Yingbei Chen, Steven Yea, Elisa Wurmbach, Myron Schwartz, Gregory Khitrov, Augusto Villanueva, Goutham Narla, Samuel Waxman, Scott L. Friedman, Josep M. Llovet
Journal: Cancer Research (2006)

2676  Hepatocellular carcinoma (HCC) is major cancer worldwide whose incidence is rapidly increasing due to end-stage chronic hepatitis C virus (HCV) infection. There is no first line systemic treatment for advanced HCC. Knowledge of of the signaling pathways involved in the initiation/progression of HCC will provide a rationale for the design of new molecular targeting agents. In order to characterize the changes in gene expression during the development of HCV-associated HCC, we collected samples from 78 HCV-cirrhotic patients undergoing surgical resection or liver transplantation for HCC. Gene expression of 56 candidate tumor pathway mRNAs were analyzed by real-time RT-PCR in lesions representing progressive histologic stages (10 normal, 10 cirrhosis, 18 dysplastic lesions, 40 HCCs) of HCC. Among these, key components of the hedgehog (Hh) signaling pathway, a tumor promoting pathway not previously studied in HCC, were, significantly dysregulated. The Hh pathway is crucial for normal embryonic development; however, reactivation of Hh signaling in adults is associated with several sporadic tumors. We found that 24/40 (60%) of HCV-associated HCCs displayed two-fold or more upregulation of Indian Hedgehog (IHH, Hh ligand) expression compared to 1/28 (3.6%) of cirrhotic livers and dysplastic lesions (p
Health-Related Quality of Life in Adolescent and Young Adult Patients With Cancer: A Longitudinal Study
Authors: Olga Husson, Brad J. Zebrack, Rebecca Block, Leanne Embry, Christine Aguilar, Brandon Hayes-Lattin, Steve Cole
Journal: Journal of Clinical Oncology (2017)

Purpose To examine changes in health-related quality of life (HRQoL) and its predictors during the first 2 years after initial cancer diagnosis in adolescent and young adult (AYA) patients with cancer. Patients and Methods A multicenter, longitudinal, prospective study was conducted among a diverse sample of AYA patients with cancer ages 15 to 39 years. One hundred seventy-six patients (75% response) completed a self-report measure of HRQoL (Short Form-36 [SF-36]) within the first 4 months after diagnosis and again 12 and 24 months later. Linear mixed models with random intercepts and slopes estimated changes in QoL. Results Recently diagnosed AYA patients with cancer had significantly worse physical component scale (PCS) scores (38.7 v 52.8; P < .001) and mental component scale (MCS) scores (42.9 v 48.9; P < .001) when compared with population norms. Significant improvements in PCS and MCS scores from baseline to 24-month follow-up were observed; however, these increases were largest during the first 12 months. At the 24-month follow-up, AYA patients still had significantly lower PCS scores (48.0 v 52.8; P < .001) and MCS scores (45.8 v 48.9; P = .002) when compared with population norms. Multivariable analyses revealed that improvements in PCS and MCS scores were primarily a function of being off-treatment and being involved in school or work. PCS but not MCS scores were worse for AYA patients diagnosed with cancers with poorer prognoses. Conclusion Although HRQoL improved over time, it was still compromised 24 months after primary diagnosis. Given relatively little observed improvement in HRQoL during the 12- to 24-month period after diagnosis, AYA patients may benefit from supportive care interventions administered during the second year after diagnosis.
CREB Controls C/Ebpd to Impair Myeloid Differentiation Process in Acute Myeloid Leukemia
Authors: Claudia Tregnago, Elena Manara, Valeria Bisio, Chiara Borga, Silvia Bresolin, Sanja Aveic, Giuseppe Germano, Giuseppe Basso, Pigazzi Martina
Journal: Blood (2015)
Validation of the CAM-ICU as performed by bed-side ICU nurses : A multicentre study
Authors: M. van Eijk, M. van den Boogaard, P. Benner, P. Eikelenboom, P. van Gool, B. van der Hoven, G. Izaks, M. Honing, J. Horn, A. Kalf, A. Karakus, I. Klijn, M. Kuiper, F. E. de Leeuw, T. de Man, R. van Marum, R. van der Mast, R. J. Osse, S. de Rooij, P. Spronk, P. van der Voort, A. Slooter
Journal: Intensive Care Medicine (2010)
Precision oncology for acute myeloid leukemia using a knowledge bank approach
Authors: Moritz Gerstung, Elli Papaemmanuil, Inigo Martincorena, Lars Bullinger, Verena I Gaidzik, Peter Paschka, Michael Heuser, Felicitas Thol, Niccolo Bolli, Peter Ganly, Arnold Ganser, Ultan McDermott, Konstanze Döhner, Richard F Schlenk, Hartmut Döhner, Peter J Campbell
Journal: Nature Genetics (2017)
It’s a long way to the top (if you want to personalize immunotherapy)
Authors: Sarah Haebe, Oliver Weigert
Journal: Journal for ImmunoTherapy of Cancer (2017)

Harnessing the immune system to attack tumor cells by targeting tumor-associated or –preferably– tumor-specific antigens has emerged as a promising but challenging treatment option for malignant lymphomas. Follicular lymphoma is among the most common lymphomas worldwide and remains incurable for most patients. Considered to be an immunogenic disease it represents an interesting disease entity for various immunotherapeutic approaches. In an article published in the May issue of <i>Clinical Cancer Research</i>, Nielsen and colleagues provided important proof-of-principle data on the immunogenicity of follicular lymphoma that might represent a first step towards personalized adoptive immunotherapies in this disease. The authors combined targeted next-generation sequencing and in silico analyses to explore the concept of somatic neoepitope prediction. Neoantigen-specific CD8<sup>+</sup> T-cells could be identified in a small subset of patients selected for in vitro immunogenicity experiments, however at remarkably low frequencies and in only a few patients at single time-points. Of note, the immunogenic neoepitopes were derived from mutant <i>CREBBP</i> and <i>MEF2B</i>, two genes that have previously been shown to be functionally and prognostically relevant in this disease. In this commentary we discuss the promises but also the challenges of how to translate these findings into clinical practice.
Favorable Immune Signature in CLL Patients, Defined By Antigen-Specific T-Cell Responses, Might Prevent Secondary Skin Cancers
Authors: Juliane S Stickel, Daniel Johannes Kowalewski, Heiko Schuster, Stefan Kahn, Linus Backert, Lothar Kanz, Helmut R Salih, Hans-Georg Rammensee, Stefan Stevanovic
Journal: Blood (2015)
Osimertinib benefit inEGFR-mutant NSCLC patients withT790M-mutation detected by circulating tumour DNA
Authors: J. Remon, C. Caramella, C. Jovelet, L. Lacroix, A. Lawson, S. Smalley, K. Howarth, D. Gale, E. Green, V. Plagnol, N. Rosenfeld, D. Planchard, M.V. Bluthgen, A. Gazzah, C. Pannet, C. Nicotra, E. Auclin, J.C. Soria, B. Besse
Journal: Annals of Oncology (2017)
Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease
Authors: Li Yu, Meifeng Tu, Jorge Cortes, Zijun Y. Xu-Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva Neelapu, Prajwal C. Boddu, Mary A. Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young
Journal: Blood (2017)
Upfront 28-Day Metronomic Therapy for High-Risk Multiple Myeloma (HRMM)
Authors: Sharmilan Thanendrarajan, Daisy V. Alapat, Maurizio Zangari, Carolina Schinke, Christoph Heuck, Frits van Rhee, Adam Rosenthal, Joshua Epstein, Shmuel Yaccoby, Faith E Davies, Gareth J Morgan, Bart Barlogie
Journal: Blood (2015)
Lack of Association Between the 46/1 JAK2 Haplotype and the Presence of JAK2V617F Mutation In Splanchnic Vein Thrombosis Patients
Authors: Eirini G Kouroupi, Bruno Cassinat, Aurelie Plessier, Sylvia Bellucci, Christine Chomienne, Bernard Granchamp, Dominique Valla, Jean-Jacques Kiladjian
Journal: Blood (2010)
Evaluation of the Ras/B-Raf/SHP-2 Axis in B Cell Malignancies.
Authors: Constantine S. Mitsiades, Nicholas Mitsiades, Galinos Fanourakis, Athina Goudopoulou, Ciaran J. McMullan, Gerasimos Voutsinas, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2004)
Full‐Thickness Heart Repair with an Engineered Multilayered Myocardial Patch in Rat Model
Authors: Seokwon Pok, Igor V. Stupin, Christopher Tsao, Robia G. Pautler, Yang Gao, Raymond M. Nieto, Ze‐Wei Tao, Charles D. Fraser, Ananth V. Annapragada, Jeffrey G. Jacot
Journal: Advanced Healthcare Materials (2017)

In a rat model of right free wall replacement, the transplantation of an engineered multilayered myocardial patch fabricated from a polycaprolactone membrane supporting a chitosan/heart matrix hydrogel induces significant muscular and vascular remodeling and results in a significantly higher right ventricular ejection fraction compared to use of a commercially available pericardium patch.
Crosstalk between Chronic Lymphocytic Leukemia (CLL) B-Cells and Marrow Stromal Cells: Implication for CLL B-Cell Activation and Survival.
Authors: Wei Ding, Grzegorz S. Nowakowski, Jennifer L. Abrahamzon, Linda E. Wellik, Asish K. Ghosh, Charla R. Secreto, Kay L. Medina, Tait D. Shanafelt, Clive S. Zent, Neil E. Kay
Journal: Blood (2007)
Combined expression of bcl-2, bcl-6, HIF, HGF, c-kit, neu/cerb2 and VEGF-C and their clinical significance in laryngeal squamous cell carcinoma
Authors: I. O. Kara, A. Uguz, B. Sahin, E. Kilic-Bagir, M. Erkisi
Journal: Journal of Clinical Oncology (2006)

20079 Background: Proteins regulating the cell cycle and cell death are frequently abnormally expressed in cancer. Several of these, particularly Bcl-2, Bcl-6, neu/cerb2 have been widely suggested as possible prognostic markers in diverse human malignancies. Their role in predicting outcome in squamous cell carcinomas of the head and neck is unclear. In addition c-kit protein has been shown in tumorogenesis. Because HNSCC preferentially metastasizes to regional lymph nodes, we investigated the expression of bcl-2, bcl-6, HIF, HGF, c-kit, neu/cerb2 and VEGF-C and their clinical significance in laryngeal squamous cell carcinomas by semiquantitative immunohistochemistry. Methods: We studied 115 patients with stage I o III tumors, all were treated with surgery ± postoperative irradiation/chemotherapy by a single institute. We studied the patients retrospectively to test the association between expression of Bcl-2, bcl-6, HIF, HGF, c-kit, neu/cerb2 and VEGF-C, as assessed by immunohistochemistry in formalin-fixed paraffin-embedded tissue and evaluated by two pathologist. We scored the expression of the proteins from negativ to severe expression. In addition we evaluated the degree of tumor grade, necrosis and also inflamation, respectively. Results: Within 115 patients we found severe expression of bcl-2 in 2 (1%), bcl-6 in 16 (13%), HIF in 57 (49%), HGF in 38 (33%), c-kit in 4 (3%), neu/cerb2 in 17 (14%) and VEGF-C in 11 (9%) patients, respectively. We found significant correlation between bcl-2 and necrosis (p = 0.003), HGF and inflamation (p = 0.05), c-kit and necrosis (p = 0.04), c-kit and tumor grade (p = 0.03) respectively. We found that the significant relation between bcl-6 and HIF (p = 0.000), bcl-6 and HGF (p = 0.02), bcl-6 and c-kit (p = 0.005), bcl-6 and VEGF-C (p = 0.000), HGF and VEGF-C (p = 0.005) respectively. Also we found that the significant correlation between tumor grade and HGF (p = 0.05). Conclusion: These data indicate that assessing expression of bcl-2 or bcl-6, c-kit and HGF is unlikely to be prognostically useful for surgically treated laryngeal carcinoma. No significant financial relationships to disclose.
Kiler Immunoglobulin Receptor(KIR) Ligands Are Associated with At Least Partial (HLA A*03, B*44) or Poorer (HLA B*51, C*04) Response to Thalidomide Among Patients with Multiple Myeloma Treated in Two Turkish Centers
Authors: Elif Suyani, Sule Mine Bakanay, Klara Dalva, Ezgi Cakmak, Rauf Haznedar, Gulsan Sucak, Meral Beksac
Journal: Blood (2012)
Identification of a Stroma-Mediated Wnt Signal Promoting Self-Renewal of Hematopoietic Stem Cells in the Stem Cell Niche.
Authors: Young-Ju Kang, Eek-hoon Jho, Hanjun Kim, Gyeongsin Park, Jae-Seung Shim, Il-Hoan Oh
Journal: Blood (2007)
A Prospective, Randomized, Chemoprevention Trial of Celecoxib for High Risk Monoclonal Gammopathy of Undetermined Significance and Asymptomatic Multiple Myeloma
Authors: Leonard J. Horwitz, Beth Faiman, Paul Elson, Rachid Baz, Mohamad Hussein, John A Lust, Paulette Mehta, Frederic J. Reu, Becky Habecker, Janice Reed, Mary Ann Karam, Robert M Dean, Ronald Sobecks, Eric D. Hsi, Varsha Kaushal, Matt Kalaycio
Journal: Blood (2012)
Myeloma in the Octogenarians: Disease Characteristics and Clinical Outcomes in the Era of Modern Anti-Myeloma Therapy
Authors: Meletios A. Dimopoulos, Evangelos Terpos, Maria Gavriatopoulou, Despoina Kalapanida, Evangelos Eleutherakis-Papaiakovou, Maria Roussou, Despoina Mparmparoussi, Athanasios Zomas, Dimitra Gika, Zafiris Kartasis, Charis Matsouka, Evangelos Kostis, Sofoklis Kontogiannis, Kostas Konstantopoulos, Efstathios Kastritis
Journal: Blood (2014)
ANGI-03OBSERVATION OF GLIOMA STEM CELLS TRANSFORM INTO ENDOTHELIAL CELLS VIA LIVE CELL IMAGING
Authors: Xin Mei, Yinsheng Chen, Zhongping Chen
Journal: Neuro-Oncology (2015)

BACKGROUND AND OBJECTIVE: We have found, in previous study, there were four types of microcirculation pattern in human glioblastoma: endothelium dependent vessels, tumor cell dependent vessels, extracellular matrix (ECM) dependent vessels, and mosaic vessels. This study is, by utilizing live cell imaging technique, to visualize the differentiation of glioma stem cells (GSCs) into endothelial cells. METHODS: Live cell imaging was used to record the transforming process of GSCs. The immunofluorescence staining was also performed to evaluate the differentiation phenomenon during GSCs three dimensional culture at time points of 0 hour, 2 hours and 6 hours. RESULTS: Tubular structures were observed in GSC-1 three dimensional culture, which was derived from a GBM patient. Some GSC-1 cells were found endothelial maker CD34 expression, and lost stem phenotype following three dimensional culture. The number of CD34+ cells were increased, and reach to highest up to 6-hour three dimensional culture (P < 0.05). Two main phenomenon were recorded by live cell imaging: (1) the number of CD34+ cells was gradually increasing following GSCs three dimensional culture; (2) The process of a single GSC-1 cell from CD34- to CD34+ . CONCLUSIONS: The result of live cell imaging has confirmed the results from conventional immunofluorescence staining that glioma stem cell may differentiate into endothelial cells, suggesting that GSCs could contribute to vasculargenesis in GBM.
Combined Intravenous Thrombolysis and Thrombectomy vs Thrombectomy Alone for Acute Ischemic Stroke
Authors: Jonathan M. Coutinho, David S. Liebeskind, Lee-Anne Slater, Raul G. Nogueira, Wayne Clark, Antoni Dávalos, Alain Bonafé, Reza Jahan, Urs Fischer, Jan Gralla, Jeffrey L. Saver, Vitor M. Pereira
Journal: JAMA Neurology (2017)

<h3>Importance</h3> Mechanical thrombectomy (MT) improves clinical outcomes in patients with acute ischemic stroke (AIS) caused by a large vessel occlusion. However, it is not known whether intravenous thrombolysis (IVT) is of added benefit in patients undergoing MT. <h3>Objective</h3> To examine whether treatment with IVT before MT with a stent retriever is beneficial in patients undergoing MT. <h3>Design, Setting, and Participants</h3> This post hoc analysis used data from 291 patients treated with MT included in 2 large, multicenter, prospective clinical trials that evaluated MT for AIS (Solitaire With the Intention for Thrombectomy performed from January 1, 2010, through December 31, 2011, and Solitaire Flow Restoration Thrombectomy for Acute Revascularization from January 1, 2010, through December 31, 2012). An independent core laboratory scored the radiologic outcomes in each trial. <h3>Interventions</h3> Patients were treated with IVT with tissue plasminogen activator followed by MT (IVT and MT group) with the use of a stent retriever or MT with a stent retriever alone (MT group). <h3>Main Outcomes and Measures</h3> Successful reperfusion, functional independence (modified Rankin Scale score of 0-2) and mortality at 90 days, symptomatic intracranial hemorrhage, emboli to new territory, and vasospasm were compared. <h3>Results</h3> Of 291 patients included in the analysis, 160 (55.0%) underwent IVT and MT (mean [SD] age, 67 [13] years; 97 female [60.6%]), and 131 (45.0%) underwent MT alone (mean [SD] age, 69 [12] years; 71 [55.7%] female). Median Alberta Stroke Program Early CT Score at baseline was lower in the IVT and MT group (8 vs 9,<i>P</i> = .04). There was no statistically significant difference in the duration from symptom onset to groin puncture (254 minutes for the IVT and MT group vs 262 minutes for the MT group,<i>P</i> = .10). The number of passes, rate of successful reperfusion, functional independence at 90 days, mortality at 90 days, and emboli to new territory were also similar among groups. Symptomatic intracranial hemorrhage (1% vs 4%) and parenchymal hemorrhages type 1 (1% vs 3%) or type 2 (1% vs 2%) did not differ significantly (<i>P</i> = .25). Vasospasm occurred more often in patients who received IVT and MT vs MT alone (27% vs 14%,<i>P</i> = .006). In multivariate analysis, no statistically significant association was observed between IVT and MT vs MT alone for any of the outcomes. <h3>Conclusions and Relevance</h3> The results indicate that treatment of patients experiencing AIS due to a large vessel occlusion with IVT before MT does not appear to provide a clinical benefit over MT alone. A randomized clinical trial seems warranted. <h3>Trial Registration</h3> clinicaltrials.gov Identifiers:NCT01054560andNCT01327989
Synergy Between Specific Inflammatory Cytokines, IFNγ and TNFα, and Iron Restriction in Erythroid Blockade: A New Model for Anemia of Chronic Disease.
Authors: Chante Richardson, Grant C. Bullock, Lorrie L Delehanty, Anne-Laure Talbot, Kamaleldin E Elagib, Jeremy Rubinstein, Adam Goldfarb
Journal: Blood (2009)
TLT-1 (TREM-Like transcript-1) Protects against Hemorrhage Associated with Inflammation by Facilitating Platelet Aggregation.
Authors: A. Valance Washington, Sébastien Gibot, Ismael Acevedo, Alina De La Mota, James Gattis, Linette Rivera, Laura Quigley, Julio Gomez-Rodriguez, Jun Cheng, Amalia Dutra, Jacek Lubkowski, Evgenia Pak, Robert Hunter, Pamela L Schwartzberg, Daniel W McVicar
Journal: Blood (2008)